- Report: Giant Eagle expanding into Indianapolis market
- Giant Eagle to bring Market District, GetGo concepts to Indianapolis
- Indiana establishes rules for the substitution of interchangeable biologic medicines
- Actavis seeks approval for generic testosterone-replacement drug
- Indiana Senate passes generic biologic pathway legislation
INDIANAPOLIS — Two senior leaders at Eli Lilly are retiring, the company said Tuesday.
The Indianapolis-based drug maker announced the Dec. 31 retirements of Lilly SVP and Bio-Medicines president Bryce Carmine, and president of manufacturing operations Frank Deane. Carmine and Deane have worked at Lilly for 36 years and 33 years, respectively. Lilly USA president Dave Ricks will replace Carmine, while SVP global drug product manufacturing Maria Crowe will replace Deane.
"We'll certainly miss Bryce and Frank and the extraordinary leadership they provided," Lilly chairman, president and CEO John Lechleiter said. "At the same time, we're very fortunate to have talented leaders who are well prepared and ready to step into these critical roles."